Friedrich-alexander-universitaet Erlangen-nuernberg

Licentia, Ltd.

Next Biomed Therapies Oy

Next Biomed Technologies Nbt Oy

Friedrich-Alexander-Universitat Erlangen-Nürnberg

Kalle Saksela

Gerold Schuler

Andreas Baur

Marita Hiipakka

The present invention is directed to SH3 domain derivatives having a specific binding affinity to a target molecule. In this respect, the invention provides SH3 domain derivatives of nephrocystin (NPHP1) and the Tec kinase. The invention also provides a method for the production of a library comprising recombinant derivatives of NPHP1 or the Tec kinase SH3 domains and a method for selecting from the library one or more derivatives of the SH3 domain of nephrocystin (NPHP1) or the Tec kinase having a specific binding affinity to a target molecule.

SH3 domain derivatives

The present invention relates to a method for in vitro detection and/or monitoring of a disease in a sample, based on measurement of enzymatic activity of proteases activated and secreted upon disease development, to modified peptides used for the enzymatic detection of the proteases, the use of the peptides, a kit comprising such peptides and the use of ADAM-protease activity as a surrogate marker for disease burden and activity in infectious, inflammatory, and malignant diseases, such as HIV infection and melanoma.

Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles

The present invention provides multiepitope-binding fusion polypeptides for use in a method for the detection of the presence of human immunodeficiency virus, HIV, in a biological sample. The present invention also provides a method for producing multiepitope-binding fusion polypeptides.

Fusion polypeptide for detection of conserved combinatorial or composite epitopes in non-conserved proteins

The present invention relates to controlled modification of Src homology region 3 (SH3) domains by using random manipulation of the non-conserved region of SH3 RT-loop. Consequently, the invention concerns methods and materials for generating SH3 do-mains with engineered binding properties, and their use as tools in research, diagnostics, therapy and drug discovery.

Growing community of inventors

Espoo, Finland

Kalle Saksela